Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $136.88

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned a consensus rating of “Buy” from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $136.88.

A number of research firms have issued reports on ASND. BidaskClub upgraded Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 30th. Wedbush lifted their price target on Ascendis Pharma A/S from $219.00 to $223.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Canaccord Genuity lifted their price target on Ascendis Pharma A/S from $133.00 to $144.00 and gave the company a “buy” rating in a research note on Friday, May 31st. Zacks Investment Research downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $185.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 18th.

Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $204,000. venBio Select Advisor LLC lifted its position in shares of Ascendis Pharma A/S by 0.8% during the 4th quarter. venBio Select Advisor LLC now owns 1,980,000 shares of the biotechnology company’s stock worth $124,047,000 after buying an additional 16,664 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in shares of Ascendis Pharma A/S by 208.2% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,131,107 shares of the biotechnology company’s stock worth $133,131,000 after buying an additional 764,160 shares in the last quarter. Morgan Stanley lifted its position in shares of Ascendis Pharma A/S by 53.6% during the 3rd quarter. Morgan Stanley now owns 47,100 shares of the biotechnology company’s stock worth $3,338,000 after buying an additional 16,434 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Ascendis Pharma A/S by 1.2% during the 4th quarter. FMR LLC now owns 4,203,246 shares of the biotechnology company’s stock worth $263,333,000 after buying an additional 50,984 shares in the last quarter.

ASND stock opened at $108.41 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 22.32 and a quick ratio of 22.32. Ascendis Pharma A/S has a 52-week low of $53.21 and a 52-week high of $133.96. The company’s 50-day moving average is $123.29.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 30th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.44). The company had revenue of $6.15 million for the quarter, compared to analyst estimates of $0.66 million. Ascendis Pharma A/S had a negative net margin of 901.89% and a negative return on equity of 34.64%. On average, analysts forecast that Ascendis Pharma A/S will post -5.42 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: Holder of Record

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.